Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction.

In post hoc analyses, sacubitril/valsartan showed a trend towards improved outcomes in patients who initiated treatment in proximity to the index hospitalisation or had an EF ≤57% and eGFR ≤45 mL/min/1.73 m 2 , although these findings remain exploratory and should be interpreted with caution. 75 76) Pooled analyses of PARADIGM-HF and PARAGON-HF, which included patients across the full EF spectrum, further support that the therapeutic effects of sacubitril/valsartan on HF hospitalisation vary by EF, with the greatest benefits observed in patients with EF below the normal range (approximately ≤55%). 77) Based on these findings, the U.S.

also in 53,322 other papers